Innovation Pathway? Why Not Fix Expedited Review, AdvaMed Suggests
FDA should improve its existing expedited review process for medical devices before investing its limited resources in a brand new innovation pathway, AdvaMed says.
FDA should improve its existing expedited review process for medical devices before investing its limited resources in a brand new innovation pathway, AdvaMed says.